Teva Pharmaceutical Industries (TEVA) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Analyst target reached at $35.62 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: generic medicines (55.0%).
Teva Pharmaceutical operates globally across U.S., Europe, and International Markets segments, generating $9,421M (55% of 2025 revenues) from generic medicines and the balance from innovative drugs (AUSTEDO, AJOVY, UZEDY, COPAXONE), biosimilars, and OTC products. Headquartered... Read more
Sell if holding. Analyst target reached at $35.62 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: generic medicines (55.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.8/10, moderate confidence.
Passes 5/6 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductgeneric medicines55%10-K Item 1A: 'In 2025, total revenues from sales of our generic medicines in all our business segments were $9,421 million, or 55% of our total revenues.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $35.62 — A.R:R is negative (-0.4) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: generic medicines (55.0%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $33.22. Score 5.8/10, moderate confidence.
Take-profit target: $34.91 (-1.3% upside). Prior stop was $33.22. Stop-loss: $33.22.
Concentration risk — Product: generic medicines (55.0%); Analyst target reached - limited upside remaining; Leverage penalty (D/E 2.2): -1.5.
Teva Pharmaceutical Industries trades at a P/E of 26.4 (forward 11.3). TrendMatrix value score: 6.1/10. Verdict: Sell.
7 analysts cover TEVA with a consensus score of 4.1/5. Average price target: $38.
What does Teva Pharmaceutical Industries do?Teva Pharmaceutical operates globally across U.S., Europe, and International Markets segments, generating $9,421M (55%...
Teva Pharmaceutical operates globally across U.S., Europe, and International Markets segments, generating $9,421M (55% of 2025 revenues) from generic medicines and the balance from innovative drugs (AUSTEDO, AJOVY, UZEDY, COPAXONE), biosimilars, and OTC products. Headquartered in Israel with ~34,000 employees across 57 markets, Teva carries $16.8B in total debt and is executing its Pivot to Growth strategy.